Bhaswati Mukherjee

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Glycemic Control

Top Venues

Diabetes therapy : research, treatment and education of diabetes and related disorders

Diabetes, obesity & metabolism

Journal of diabetes science and technology

This page only lists publications with an associated author ORCID identifier.

Publications

Viral N Shah, Amer Al-Karadsheh, Cathy Barnes, Jose Mandry, Samer Nakhle, Karin Wernicke-Panten, Daniel Kramer, Wolfgang Schmider, Suzanne Pierre, Lenore Teichert, Baerbel Rotthaeuser, Bhaswati Mukherjee, Timothy S Bailey
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. Journal of diabetes science and technology (2024)
Viral N Shah, Amer Al-Karadsheh, Cathy Barnes, Jose Mandry, Samer Nakhle, Karin Wernicke-Panten, Daniel Kramer, Wolfgang Schmider, Suzanne Pierre, Lenore Teichert, Baerbel Rotthaeuser, Bhaswati Mukherjee, Timothy S Bailey
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes, obesity & metabolism (2023)
S R Aravind, Kiran P Singh, Grace Aquitania, Liliia Mogylnytska, Alsu G Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M). Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (5) (2022)
Tadej Battelino, Thomas Danne, Steve V Edelman, Pratik Choudhary, Pr Eric Renard, Jukka Westerbacka, Bhaswati Mukherjee, Valerie Pilorget, Mathieu Coudert, Richard M Bergenstal
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial. Diabetes, obesity & metabolism (2022)
S R Aravind, Kiran P Singh, Liliia Mogylnytska, Alsu G Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (7) (2022)
Viral N Shah, Edward Franek, Karin Wernicke-Panten, Suzanne Pierre, Bhaswati Mukherjee, Karita Sadeharju
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders 12 (2) (2021)
Christoph Kapitza, Leszek Nosek, Wolfgang Schmider, Lenore Teichert, Bhaswati Mukherjee, Irene Nowotny
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes. Diabetes, obesity & metabolism 23 (3) (2020)